Financial Performance - Company reported net sales of $766.5 million for the second quarter of 2025, an increase of 9.2% compared to the same period last year, with organic net sales growth of 6.8% [12][19] - Diluted EPS for the quarter was $1.82, up from $1.51 in the prior year, while adjusted-diluted EPS increased to $1.84 from $1.52 [12][19] - Operating cash flow for the first six months of 2025 was $306.5 million, an increase of 8.2% year-over-year, with free cash flow rising to $160.0 million from $92.4 million [7][28] Segment Performance - Proprietary Products segment net sales grew by 10.7% to $619.8 million, with High-Value Product (HVP) components accounting for 47% of total sales and increasing by 11.3% [4][20] - Contract-Manufactured Products segment saw a 3.0% increase in net sales to $146.7 million, driven by self-injection devices for obesity and diabetes [6][20] Guidance and Future Outlook - Company raised its full-year 2025 net sales guidance to a range of $3.040 billion to $3.060 billion, up from the previous range of $2.945 billion to $2.975 billion [12][13] - Adjusted-diluted EPS guidance for 2025 was also increased to a range of $6.65 to $6.85, up from $6.15 to $6.35 [12][13] Shareholder Returns - The Board of Directors approved a fourth-quarter 2025 dividend of $0.22 per share, payable on November 19, 2025, to shareholders of record as of November 12, 2025 [12][13] Financial Condition - As of June 30, 2025, the company had cash and cash equivalents of $509.7 million, accounts receivable of $582.4 million, and inventories of $421.1 million [29]